DPP4i treatment made simple.

TRAJENTA® (linagliptin) belongs to the class of oral anti-diabetic medications called DPP4 inhibitors (DPP4i).

DPP4i prolong the action of incretins (GLP-1 and GIP), and by working in a glucose dependent way they:1,2
Blue arrow
Increase glucose dependent insulin secretion leading to increased glucose utilization by muscle and adipose tissue.
Yellow arrow
Increase glucose dependent glucagon suppression leading to decreased hepatic glucose release improving overall glucose control.
GLP-1: glucagon-like peptide-1; GIP: glucose-dependent insulinotropic polypeptide.

Thanks to this mode of action, DPP4i are generally associated with:3

TRAJENTA® (linagliptin) proven efficacy on HbA1C
TRAJENTA® presents a very low risk for hypoglycaemia
TRAJENTA® DPP4i are generally associated with favourable safety and tolerability profile

TRAJENTA® is different from most of the other DPP4i because it is the only DPP4i primarily excreted via a non-renal route. No dose adjustment makes TRAJENTA® simple to use:4

TRAJENTA® no dose adjustment required in patients with renal impairment
TRAJENTA® No requirement for additional drug-related renal function monitoring